

**CLINICAL AND INSTRUMENTAL EVALUATION OF THE
ANTI-AGING EFFICACY OF A NIGHT CREAM TESTED ON
TIRED SKIN.
CONTROLLED STUDY VS PLACEBO**

RIVOLI COSMÉTIQUES SA

Crème de Nuit Jeunesse N°02 lab-01759.18



KEY PERSONNEL

Customer

RIVOLI COSMÉTIQUES SA
14 Rue de L'arquebuse
1204 Genève
Switzerland

Principal experimenter

Dr Enza CESTONE
Degree in Medicine and Surgery, Specialist in Dermatology and Venereology
Consultant to Complife Italia S.r.l.

Data analysis and report

Dr Federica RUGGERI
Biologist
Complife Italia S.r.l.

Quality control

Dr Francesca DE GENNARO
Biologist
Complife Italia S.r.l.

Complife Italia S.r.l.

Via Angelini, 21
27028 San Martino Siccomario (PV) Italy
tel. +39-0382 25504
Mail: info@complifegroup.com



INDEX

STUDY DESIGN	4
1.1. Title	4
1.2. Aim of the study	4
1.3. Test product.....	4
1.3.1. Information provided by the Customer.....	4
1.4. Ethical requirements	4
1.5. Subjects participating in the study	5
1.5.1. Subjects' enrolment.....	5
1.5.1.1. Inclusion criteria	5
1.5.1.2. Non-inclusion criteria	5
1.5.1.3. Withdrawal of subjects.....	6
1.6. Study development	6
1.7. Materials and methods	6
1.7.1. Skin pH.....	6
1.7.2. Skin moisturization	6
1.7.3. Skin radiance/brightness	6
1.7.4. Skin elasticity/firmness.....	7
1.7.5. Skin profilometry	8
1.7.6. Transepidermal water loss - TEWL	8
1.7.7. Self-assessment	8
1.8. Results and statistics	9
1.8.1. Results	9
1.8.2. Statistical analysis.....	9
1.8.3. Interpretation of results	9
1.9. Start/end date of study	9
1.10. Report change record.....	10
PANEL DEMOGRAPHY.....	11
RESULTS:.....	12
SKIN pH	12
SKIN MOISTURIZATION.....	14
SKIN RADIANCE/BRIGHTNESS – GLOSS PARAMETER	16
SKIN FIRMNESS – R0 PARAMETER	18
SKIN ELASTICITY – R2 PARAMETER.....	20
SKIN PROFILOMETRY: SKIN SMOOTHNESS - Ra PARAMETER.....	22
SKIN PROFILOMETRY: SKIN ROUGHNESS – Rz PARAMETER.....	24
TRANSEPIDERMAL WATER LOSS.....	26
SELF-ASSESSMENT QUESTIONNAIRE	28
CONCLUSIONS	32



STUDY DESIGN

1.1. Title

Clinical and instrumental evaluation of the anti-aging efficacy of a night cream tested on tired skin. Controlled study vs placebo.

1.2. Aim of the study

The study is aimed to evaluate the efficacy of a cosmetic active product (night cream) aimed to improve skin aspect and reduce tiring signs in subjects complaining lack of sleep.

In order to reach this goal, a clinical-instrumental placebo-controlled study is carried out on 35 healthy female subjects aged between 35 and 45 (± 2) complaining lack of sleep (volunteers working on shifts, with lack of sleep due to familiar or working conditions with Pittsburgh Sleep Quality Index - PSQI > 5 - bad sleepers) showing tired skin (fine lines/slight wrinkles, dull skin, slightly dry/dry skin).

The study foresees both a short-term and a long-term test; instrumental evaluations are carried out at baseline (T0), 15 minutes after the first product application (T15min, only for skin pH), the morning after the first use (only for self-assessment) and after 7 (T7) and 28 days (T28 days of use).

Products effect and efficacy are evaluated by means of bioengineering techniques able to measure skin radiance/brightness, skin profilometry, skin elasticity and firmness, skin moisturization, transepidermal water loss and skin pH. Moreover, volunteers are asked to fill in a self-assessment questionnaire.

1.3. Test product

1.3.1. Information provided by the Customer

- ☒ Products identification: **Crème de Nuit Jeunesse N°02 lab-01759.18 (tested product)**
Crème de Nuit N. 02 01759.20 (placebo)

- ☒ Way of use: in the evening massage on half left or right half-face, from the centre outwards, while on the other half apply the placebo cream (according to the predefined randomization scheme).

To standardize test conditions, in the morning the subjects apply a base cream without any claimed efficacy provided by Complife.

- ☒ The cosmetic products to be tested conform to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance) and to its annexes.

- ☒ The cosmetic products to be tested are safe under normal or reasonably foreseeable conditions of use.

- ☒ INCI formula:

01759.18: AQUA (WATER), OCTYLDODECANOL, GLYCERIN, SQUALANE, PROPANEDIOL, BUTYROSPERMUM PARKII (SHEA) BUTTER, CAPRYLIC/CAPRIC TRIGLYCERIDE, CETEARYL ALCOHOL, HYDROGENATED PHOSPHATIDYLCHOLINE, ISONONYL ISONONANOATE, METHYL GLUCOSE SESQUISTEARATE, BUTYLENE GLYCOL, GLYCERYL STEARATE CITRATE, PENTYLENE GLYCOL, CAPRYLYL GLYCOL, UREA, XANTHAN GUM, ETHYLHEXYLGLYCERIN, SACCHARIDE HYDROLYSATE, NIACINAMIDE, DIPROPYLENE GLYCOL, GLYCERYL CAPRYLATE, PARFUM (FRAGRANCE), DISODIUM ADENOSINE TRIPHOSPHATE, SERICOSIDE, ALANINE, GLYCINE, MAGNESIUM ASPARTATE, LESPEDEZA CAPITATA LEAF/STEM EXTRACT, TETRASODIUM GLUTAMATE DIACETATE, CERAMIDE NP, CREATINE, HYDROLYZED OATS, SODIUM HYDROXIDE, HEXAMETHYLINDANOPYRAN.

01759.20: AQUA (WATER), OCTYLDODECANOL, SQUALANE, GLYCERIN, PROPANEDIOL, BUTYROSPERMUM PARKII (SHEA) BUTTER, CAPRYLIC/CAPRIC TRIGLYCERIDE, CETEARYL ALCOHOL, HYDROGENATED PHOSPHATIDYLCHOLINE, ISONONYL ISONONANOATE, METHYL GLUCOSE SESQUISTEARATE, GLYCERYL STEARATE CITRATE, BUTYLENE GLYCOL, PENTYLENE GLYCOL, CAPRYLYL GLYCOL, XANTHAN GUM, ETHYLHEXYLGLYCERIN, DIPROPYLENE GLYCOL, GLYCERYL CAPRYLATE, TETRASODIUM GLUTAMATE DIACETATE, CERAMIDE NP, SODIUM HYDROXIDE.

1.4. Ethical requirements

The study is carried out in accordance with the following ethical requirements:

- All subjects participating in the study are healthy volunteers of at least 18 years old.
- All subjects participating in the study are selected with the supervision of a dermatologist according to inclusion/not inclusion criteria.
- Volunteers participation in the study was totally free.
- All subjects participating in the study are informed of the aim and the design of the study.
- All subjects participating in the study are informed of the possible risk involved in the study execution.



- All subjects participating in the study give their informed consent signed at the beginning of the study.
- Before volunteer exposure to the tested product, all relevant safety information about the product itself and each ingredient were collected and evaluated.
- All study procedures are carried out in compliance with the ethical principles for the medical research (Ethical Principles for Medical Research Involving Human Subjects, adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amendments).
- All precautions are taken in consideration in order to avoid excessive skin reactions.
- If any unexpected/adverse skin reaction occurs, medical investigating specialist evaluates the severity of the reaction (reporting it in the volunteer's data collecting sheet) and proceeds with appropriate therapy.

1.5. Subjects participating in the study

1.5.1. Subjects' enrolment

The subjects participating in the study are selected under the supervision of a board-certified dermatologist in accordance with the following inclusion and non-inclusion criteria.

1.5.1.1. Inclusion criteria

- ✓ Healthy female subjects
- ✓ Age between 35 and 45 (± 2)
- ✓ Subjects complaining lack of sleep (volunteers working on shifts, with lack of sleep due to familiar or working conditions)
- ✓ Subjects with Pittsburgh Sleep Quality Index - PSQI > 5 - bad sleepers*
- ✓ Subjects showing tired skin (fine lines/slight wrinkles, dull skin, slightly dry/dry skin).
- ✓ Subjects registered with National Health Service (NHS)
- ✓ Subjects certifying the truthfulness of the personal data disclosed to the investigator
- ✓ Subjects able to understand the language used in the investigation centre and the information given by the investigator
- ✓ Subjects able to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements
- ✓ The pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) should be stable for at least one month without any changes expected or planned during the study
- ✓ Commitment not to change the daily routine or the lifestyle.
- ✓ Subjects informed on the test purposes and that have signed an informed consent form.

**The Psychologist supervises the study by remote control checking the correspondence of the subjects to the inclusion criteria.*

1.5.1.2. Non-inclusion criteria

- ✗ Subject does not meet the inclusion criteria above reported
- ✗ Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements
- ✗ Subjects participating or planning to participate in other clinical trials
- ✗ Subjects deprived of freedom by administrative or legal decision or under guardianship
- ✗ Subjects not able to be contacted in case of emergency
- ✗ Subjects admitted to a health or social facility
- ✗ Subjects planning a hospitalisation during the study
- ✗ Subjects who participated in a similar study without respecting an adequate washout period
- ✗ Subjects having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- ✗ Subjects under pharmacological treatments that are considered incompatible with the study requirement by the investigator
- ✗ Subjects having a skin disease or condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- ✗ Subjects that have shown allergies or sensitivity to cosmetic products, drugs, patch or medical devices
- ✗ Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential).



1.5.1.3. Withdrawal of subjects

A subject enrolled in the study can be withdrawn and considered as a drop-out when: (i) no longer want to participate in the study, (ii) adverse reactions, judged severe and attributable to the tested product, occur, (iii) the subject is no longer eligible to participate in the study, (iv) the subject develops a pathological condition, not related to the study, but appearing during the study period, (v) it is required the prescription of a concomitant treatment, (vi) the study requirements are not satisfied (significant deviation from the protocol), (vii) significant non-compliance with respect to product use or to the study protocol.

1.6. Study development

The study is carried out as follow:

- ✓ **T0:** enrolment of 35 subjects according to inclusion/non-inclusion criteria. Instrumental evaluation of the parameters under study before product application (skin radiance/brightness, skin profilometry, skin firmness and elasticity, skin moisturization and transepidermal water).
- ✓ **First products application:** according to a predefined randomization scheme the products are applied (2 mg/cm²) under the experimenter supervision on half-face according to provided instructions.
- ✓ **T15min*:** instrumental evaluation of skin pH 15 minutes after the single products application.
- ✓ **Products application at home:** in the evening (before going to bed) volunteers apply the products, according to provided instructions.
- ✓ **T12h:** the next morning (12 hours after product application), volunteers are asked to express their opinion on tested products by answering to a questionnaire.
- ✓ **T2-T28:** daily products use at home according to provided instructions.
- ✓ **T7:** after 7 days of product use, the instrumental evaluations of skin radiance/brightness, skin profilometry, skin firmness and elasticity, skin moisturization and transepidermal water loss are repeated.
- ✓ **T28:** after 28 days of product use, the instrumental evaluations of skin radiance/brightness, skin profilometry, skin firmness and elasticity, skin moisturization and transepidermal water loss are repeated; moreover, volunteers are asked to express their opinion on tested products by answering to a questionnaire.

*up to T15min check volunteers remain in laboratory in controlled conditions of humidity and temperature.

1.7. Materials and methods

Here below are reported the parameters monitored during the study. The study evaluations are carried out in a temperature and humidity-controlled environment (respectively T= 18-26°C and RH= 50±10%). The subject, before each visit, observes a 15-20-minute acclimatization period in these conditions.

1.7.1. Skin pH

The used instrument is the SKIN pH-METER 905®, Courage + Khazaka GmbH. The measure is based on a combined electrode of high quality, in which both the glass electrode sensitive to H⁺ and the additional reference electrode are placed in the same site. It is connected to a handle probe containing the measurement electronics. Before the measurements, the SKIN pH-meter® 905 (Courage + Khazaka electronic GmbH) is calibrated using two buffer solutions with known pH (pH 4.01 and 1.7) as reference.

Measurement range: 0 to 12; accuracy: ± 0.1 pH.

1.7.2. Skin moisturization

Skin moisturization is evaluated by means of Corneometer® measurement. This measurement is based on the completely different dielectric constant of water (81) and other substances (mostly < 7). The measuring capacitor shows changes of capacitance according to the moisture content of the skin. A metallic lamina separates the metallic tracks (gold) in the probe head from the skin in order to prevent current conduction in the measured area. An electric field between the tracks with alternating attraction develops. One track builds up a surplus of electrons (minus charge) the other a lack of electrons (plus charge). The scatterfield penetrates the very first layer of the skin (10-20 µm) during the measurement and the capacitance is determined.


1.7.3. Skin radiance/brightness

The skin radiance/brightness is the ability of the skin to reflect the light and it is measured using the gloss parameter (taken using the spectrophotometer/colorimeter CM-700D (Konica-Minolta). The instrument emits diffuse light that



reaches the skin through an opening located at the extreme of the lighting sphere. A sensor located at 8° compared to the vertical axis of the opening detects then the reflected light and calculates a parameter known as "gloss". The gloss value is used in the management of the brilliance of the colour. For further information on the principle of the measurement and data analysis see box 1.

Box 1 - Gloss parameter



When light reach a surface it is reflected at the equal but opposite angle from the light source; this is called specularly reflected light. This specular component is reflected as if reflected by a mirror. The light that is not specularly reflected, but scattered in many directions, is called diffuse reflectance (insert 1). The sum of the specular reflectance plus the diffuse reflectance is called the total reflectance. For objects with shiny surfaces, the specularly reflected light is relatively strong and the diffused light is weaker. On rough surfaces with a low gloss, the specular component is weak and the diffused light is stronger. The measuring geometry $d: 8^\circ$ features an optical device which provides diffuse illumination (Ulbricht sphere). The light (Xenon lamp) is projected into a sphere. The interior of the sphere is coated with a white highly reflecting substance (barium sulphate, ceramic, special plastic) which reflects the light manifold. A shutter, an optical element inside the sphere, prevents the directional rays from reaching the measuring sample directly. The sample is positioned at an opening of the sphere and is illuminated from all directions with a close to perfect diffuse light. Through an opening at the top of the sphere the sensor is viewing the surface being measured with an angle of 8° to the vertical. In order to prevent reflection of specular light from the sample surface, the instrument feature a gloss trap. When the trap which is arranged with an angle of -8° to the viewing opening, is open, the light which would otherwise be reflected from the interior wall of the sphere, will be eliminated and can therefore not


illuminate the sample. The relation between directional and diffuse reflection allows calculating the gloss component. The measuring system including gloss is named $d: 8^\circ$ whilst the measuring system excluding gloss is described as $de: 8^\circ$.

1.7.4. Skin elasticity/firmness

Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®MPA 580, Courage+Khazaka, electronic GmbH). During the suction/elongation phase the instrument generates, in fact, a constant negative pressure (450 mbar) able to aspirate the skin inside the measurement probe. The suction phase is followed by the release phase, in which the pressure inside the probe is switched to 0 mbar allowing the skin recovery after the elongation phase. An optical measurement system evaluates the depth of the skin inside the probe in the two phases of the measurement, the obtained data are then elaborated and showed graphically and numerically in order to calculate the viscoelastic properties of the skin. For further information see box 2.

- **R2 parameter** (gross elasticity or overall elasticity): it is the ratio between the residual deformation and the maximum elongation of the skin (U_a/U_f) and it indicates the ability of the skin to return to its original state of recovery after a stressing event. Closer the value is to 1, more elastic is the skin.
- **R0 parameter** (skin distensibility): it is the first max amplitude of the curve (U_f) and it represents the passive behaviour of the skin to a force (i.e. gravity). A reduction of R0 parameter indicates an improvement of the skin ability to oppose to the deformation imposed by the probe during the suction phase, than can be expressed as an improvement of skin firmness.


Box 2 (a) Skin elasticity measurement process. (b) R0 parameter. (c) R2 parameter.



1.7.5. Skin profilometry

Skin surface is quantitatively assessed by Primos^{CR} SF (Canfield Scientific Europe, BV, Utrecht, Netherlands). Primos 3D is a non-contact in vivo skin measurement device based on structured light projection. In conjunction with a comprehensive 3-D measurement and evaluation software, the sensor allows to evaluate skin surface properties (i.e., wrinkle depth, volume, roughness etc.). In this study Ra and Rz parameters are evaluated in the crow's feet area. For further information see box 3.


Box 3 - Skin profilometry by means of Primos 3D analysis



The technique. Primos 3D is a 3D scanner that create a point cloud (set of vertices in a three-dimensional coordinate system) of geometric samples on the surface of the subject. These points are then used to extrapolate the shape of the subject (a process called reconstruction). Like cameras, 3D-scanner has a cone-like field of view, and like cameras, they can only collect information about surfaces that are not obscured. While a camera collects color information about surfaces within its field of view, 3D scanners collect distance information about surfaces within its field of view. The "picture" produced by a 3D scanner describes the distance to a surface at each point in the picture (see the image in the insert).

Calculation of skin smoothness (Ra and Rz parameter)

For the calculation of a star roughness, intersections are arranged in a star shape by the program. The calculation of the parameter occurs accordingly to the determination of the line roughness (separate for every star shape arranged intersection). In this study skin smoothness is calculated through the Ra parameter. Ra parameter is the arithmetic average of the absolute values of the roughness profile ordinates. A decrease of this parameter indicates an improvement of skin smoothness. Rz is the arithmetic mean value of the single roughness depths Rzi of 5 consecutive sampling lengths:



Ra is mathematically calculated as:

$$R_a = \frac{1}{l} \int_0^l |Z(x)| dx$$

Rz is mathematically calculated as:

$$R_z = \frac{1}{n} (R_{z1} + R_{z2} + \dots + R_{zn})$$

1.7.6. Transepidermal water loss - TEWL

The measurement of the transepidermal water loss is based on internationally recognized TEWAMETER[®] method. The used instrument is a Tewameter 300[®] (Courage+Khazaka, electronic GmbH). Physical basis for the measurement is the Diffusion law discovered by Adolf Fick in 1855:

$$\frac{dm}{dt} = -D \cdot A \cdot \frac{dp}{dx}$$

where: A = surface in m², m = water transported (in g), t = time (h), D = diffusion constant (=0.0877 g/mhmm Hg), p = vapor pressure of the atmosphere (mm Hg), x = distance from skin surface to point of measurement (m).

The diffusion flow dm/dt indicates the mass per cm² being transported in a period of time. It is proportional to the area A and the change of concentration per distance dp/dx. D is the diffusion coefficient of water vapor in the air. This law is only valid within a homogenous diffusion zone, which is approximately formed by a hollow cylinder. The resulting density gradient is measured indirectly by two pairs of sensors (temperature and relative humidity) and is analyzed by a microprocessor. The measuring head of the probe is a narrow hollow cylinder (10 mm diameter and 20 mm height) to minimize influences of air turbulence inside the probe.

1.7.7. Self-assessment

The morning after the first product application and at the end of the study volunteers are asked to express their opinion about tested products by answering to a self-assessment questionnaire.



1.8. Results and statistics

1.8.1. Results

Results are reported in tables in their respective units.

1) Mean values are calculated as follows:

$$m = \frac{\sum_{i=1}^n p}{n}$$

where: p is the value of the parameter under analysis; n is the number of subjects participating in the study

2) Percentages are calculated as follows:

$$\%var.vs.T0 = \left(\sum_{i=1}^n \frac{p_i - p_0}{p_0} \right) \times 100$$

or

$$\%o f \text{ subjects} = \left(\frac{\sum_{i=1}^n \text{answers}}{n} \right) \times 100$$

where: p_i is the value of the parameter under analysis after product use; p₀ is the value of the parameter under analysis before product application; n is the number of subjects participating in the study

3) The standard error of data is calculated as:

$$SE = \frac{\sqrt{\frac{\sum_{i=1}^n (p_i^2) - \frac{(\sum_{i=1}^n p_i)^2}{n}}{(n-1)}}}{\sqrt{n}}$$

where: p is the value of the parameter under analysis; n is the number of subjects participating in the study

All the calculations are done using a Microsoft® Excel file.

Final self-assessment data are reported in a Microsoft® Excel sheet. The percentages of subjects that attribute a given score to a given question is calculated. Results are calculated as percentage (%) of subjects who assigned a particular judgment (among those proposed). For each question, the number of subjects related to each judgment is counted → (number of subjects) and this number is then divided by the total number of subjects → % of answers.

1.8.2. Statistical analysis

The instrumental data are submitted to the 2-way Student's test t for paired data. Variations are considered statistically significant when p value is < 0,05.

1.8.3. Interpretation of results

The study here above reported was designed to demonstrate the test product claim(s) in the current framework proposed by Commission Regulation (EU) No 655/2013. Endpoints are measured using techniques currently accepted in the cosmetic field while biases are minimized by procedure(s) standardization according to ISO 9001 Quality Management System. Data are analyzed and interpreted by skilled technician according to both descriptive and inferential statistical analysis procedures. Due to the lack of reference values in the cosmetic field, statistical significance (for instrumental analysis) and percentage of subjects showing an effect (for clinical/sensorial endpoints) are the primary criterion to evaluate the correspondence between the proposed claim(s) and the study output(s). In particular, intragroup (vs. T0) or intergroup (e.g., active vs. placebo, treated vs non treated) statistical analysis criterion to reject the null hypothesis (no product effect) is set at p<0.05. For clinical evaluations, the positive effect of the product on the evaluated parameter is confirmed if more than 50% of the subjects register an improvement. Finally, for the self-assessment questionnaires, the performance and the pleasantness of the product must be perceived by at least 60% of the subjects. rWhenever reference values or threshold values exist, those values are used to validate product claim(s).

1.9. Start/end date of study

The table here below reports date of beginning and end of the study.

Start date	End date
28/11/2023	05/04/2024



1.10. Report change record

The table here below reports the change log of all approved changes made to the document that make up the course after initial approval.

Rev. no	Date	Description
00	28/05/2024	First report release

- The results of the study reported in this document are only referred to the tested samples and the specific experimental conditions.
- Any part of this report can only be reproduced with the consent of Complife Italia S.r.l.
- A copy of this report is kept on file at Complife Italia S.r.l.
- Both the informed consent and the information forms are kept on file at Complife Italia S.r.l. for 10 years after the date of issue of the report.



PANEL DEMOGRAPHY

Table A. The following table reports the characteristics of the enrolled subjects.

no.	Vol. ID	Age	Skin type	PSQI
01	R4596I	45	DRY	6
02	F7470E	43	DRY	6
03	B4852D	39	DRY	6
04	D8536C	38	DRY	6
05	S4702R	38	DRY	6
06	M7206C	45	DRY	10
07	P6503V	45	DRY	6
08	B3231G	40	DRY	9
09	S3327S	47	DRY	12
10	G4137M	39	DRY	16
11	R0471E	41	DRY	8
12	S6987S	35	DRY	6
13	C7481S	45	DRY	6
14	M4081A	46	DRY	6
15	M1308V	35	DRY	10
16	M3862R	47	DRY	6
17	S1995S	41	DRY	6
18	B4239N	44	DRY	9
19	C0947V	36	DRY	6
20	C1227F	46	DRY	6
21	L2381A	43	DRY	16
22	G1487B	47	DRY	6
23	C4251L	44	DRY	6
24	V8704B	35	DRY	9
25	G5429D	40	DRY	6
26	G5068M	39	DRY	6
27	Z7572C	47	DRY	6
28	R7603F	44	DRY	7
29	P7628M	42	DRY	6
30	C1201L	47	DRY	6
31	P5338A	45	DRY	8
32	G8171T	42	DRY	8
33	D4546E	38	DRY	6
34	S8025S	44	DRY	6
35	B4706F	46	DRY	7
Mean		42,2		
SE		0,6		
Min		35		
Max		47		

Legend: SE Standard Error; PSQI Pittsburgh Sleep Quality Index.

Note: in this study subjects with PSQI > 5 are enrolled.



RESULTS: SKIN pH


TABLES 1a,b The tables below show the obtained data for each volunteer at each experimental time. Data are expressed in pH values.

TESTED PRODUCT				PLACEBO PRODUCT			
no.	Vol. ID	T0	T15min	no.	Vol. ID	T0	T15min
01	R4596I	6,8	6,2	01	R4596I	7,9	7,4
02	F7470E	6,5	6,7	02	F7470E	7,0	6,4
03	B4852D	6,8	6,8	03	B4852D	6,4	6,0
04	D8536C	6,9	6,1	04	D8536C	6,1	6,6
05	S4702R	6,8	6,4	05	S4702R	6,0	6,0
06	M7206C	6,3	6,6	06	M7206C	6,5	6,6
07	P6503V	6,9	6,8	07	P6503V	6,5	6,2
08	B3231G	6,1	6,0	08	B3231G	6,9	6,6
09	S3327S	6,4	5,8	09	S3327S	6,2	6,1
10	G4137M	5,7	5,7	10	G4137M	6,5	7,0
11	R0471E	6,8	7,0	11	R0471E	6,3	6,4
12	S6987S	6,3	6,8	12	S6987S	6,8	7,0
13	C7481S	6,6	6,0	13	C7481S	6,7	6,4
14	M4081A	6,5	6,5	14	M4081A	5,9	5,9
15	M1308V	6,5	6,4	15	M1308V	6,7	6,4
16	M3862R	6,6	6,1	16	M3862R	6,7	7,3
17	S1995S	6,5	6,4	17	S1995S	6,6	6,2
18	B4239N	6,2	6,3	18	B4239N	6,8	6,0
19	C0947V	6,3	6,8	19	C0947V	6,7	6,9
20	C1227F	6,1	6,2	20	C1227F	6,9	6,7
21	L2381A	6,7	6,5	21	L2381A	6,9	6,2
22	G1487B	6,8	6,6	22	G1487B	6,9	6,7
23	C4251L	6,9	6,8	23	C4251L	6,6	6,5
24	V8704B	6,2	6,4	24	V8704B	6,6	6,4
25	G5429D	7,0	6,8	25	G5429D	7,0	7,0
26	G5068M	7,0	6,6	26	G5068M	6,9	6,7
27	Z7572C	6,9	6,5	27	Z7572C	7,1	7,0
28	R7603F	6,3	6,8	28	R7603F	6,9	7,3
29	P7628M	6,4	6,6	29	P7628M	6,5	6,2
30	C1201L	6,9	7,0	30	C1201L	6,8	7,0
31	P5338A	6,8	6,6	31	P5338A	6,9	7,1
32	G8171T	6,7	5,8	32	G8171T	6,8	6,3
33	D4546E	6,6	6,5	33	D4546E	6,1	6,1
34	S8025S	6,5	6,6	34	S8025S	6,5	6,7
35	B4706F	6,9	6,6	35	B4706F	6,9	6,8
Mean		6,6	6,4	Mean		6,7	6,6
SE		0,1	0,1	SE		0,1	0,1

Legend: SE Standard Error; pl. placebo product



GRAPH 1 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE.



COMMENT

15 minutes after products application pH values remain physiological.



SKIN MOISTURIZATION


TABLES 2a,b The tables below show the obtained data for each volunteer at each experimental time. Data are expressed in corneometric units (c.u.).

TESTED PRODUCT						PLACEBO PRODUCT									
no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28	no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28
01	R4596I	27,9	43,7	43,7		56,6%	56,6%	01	R4596I	29,4	42,2	34,3		43,5%	16,7%
02	F7470E	32,7	47,8	53,8		46,2%	64,5%	02	F7470E	34,5	44,0	45,8		27,5%	32,8%
03	B4852D	37,1	49,0	48,5		32,1%	30,7%	03	B4852D	36,6	39,2	40,1		7,1%	9,6%
04	D8536C	36,6	43,4	43,6		18,6%	19,1%	04	D8536C	34,1	39,5	35,5		15,8%	4,1%
05	S4702R	36,7	47,5	47,3		29,4%	28,9%	05	S4702R	37,3	47,5	46,9		27,3%	25,7%
06	M7206C	31,3	40,3	41,9		28,8%	33,9%	06	M7206C	33,8	36,1	39,7		6,8%	17,5%
07	P6503V	38,9	53,5	55,0		37,5%	41,4%	07	P6503V	37,4	42,8	41,0		14,4%	9,6%
08	B3231G	32,3	34,1	37,0		5,6%	14,6%	08	B3231G	34,0	36,9	34,3		8,5%	0,9%
09	S3327S	27,8	36,0	37,5		29,5%	34,9%	09	S3327S	30,2	31,2	30,5		3,3%	1,0%
10	G4137M	34,8	40,1	53,4		15,2%	53,4%	10	G4137M	33,8	35,3	38,9		4,4%	15,1%
11	R0471E	37,2	40,7	50,4		9,4%	35,5%	11	R0471E	34,4	42,4	40,1		23,3%	16,6%
12	S6987S	30,8	42,9	46,3		39,3%	50,3%	12	S6987S	27,6	30,0	30,6		8,7%	10,9%
13	C7481S	31,2	41,5	42,6		33,0%	36,5%	13	C7481S	31,5	38,5	38,3		22,2%	21,6%
14	M4081A	36,7	53,6	54,0		46,0%	47,1%	14	M4081A	40,4	40,7	41,3		0,7%	2,2%
15	M1308V	38,1	43,7	53,1		14,7%	39,4%	15	M1308V	38,3	39,9	40,5		4,2%	5,7%
16	M3862R	35,6	55,9	56,3		57,0%	58,1%	16	M3862R	36,0	37,0	43,8		2,8%	21,7%
17	S1995S	38,9	40,3	47,7		3,6%	22,6%	17	S1995S	34,2	33,3	40,7		-2,6%	19,0%
18	B4239N	30,0	36,6	42,5		22,0%	41,7%	18	B4239N	30,2	30,7	40,2		1,7%	33,1%
19	C0947V	31,4	47,5	47,3		51,3%	50,6%	19	C0947V	30,7	31,8	30,3		3,6%	-1,3%
20	C1227F	36,3	40,7	55,9		12,1%	54,0%	20	C1227F	33,0	38,6	44,7		17,0%	35,5%
21	L2381A	32,7	42,7	46,4		30,6%	41,9%	21	L2381A	33,2	38,8	36,3		16,9%	9,3%
22	G1487B	40,5	43,7	51,4		7,9%	26,9%	22	G1487B	39,4	36,8	40,4		-6,6%	2,5%
23	C4251L	39,6	50,7	54,3		28,0%	37,1%	23	C4251L	37,0	40,0	40,7		8,1%	10,0%
24	V8704B	32,8	40,3	49,7		22,9%	51,5%	24	V8704B	34,2	36,6	45,9		7,0%	34,2%
25	G5429D	31,2	44,7	50,1		43,3%	60,6%	25	G5429D	29,6	33,3	33,6		12,5%	13,5%
26	G5068M	35,6	50,8	53,4		42,7%	50,0%	26	G5068M	37,2	38,5	40,3		3,5%	8,3%
27	Z7572C	36,6	36,2	45,8		-1,1%	25,1%	27	Z7572C	37,6	37,1	41,3		-1,3%	9,8%
28	R7603F	28,2	29,9	34,8		6,0%	23,4%	28	R7603F	27,4	26,1	28,6		-4,7%	4,4%
29	P7628M	33,9	48,7	49,1		43,7%	44,8%	29	P7628M	32,2	43,6	44,2		35,4%	37,3%
30	C1201L	31,8	38,9	42,3		22,3%	33,0%	30	C1201L	30,9	31,1	33,3		0,6%	7,8%
31	P5338A	36,3	46,3	47,5		27,5%	30,9%	31	P5338A	35,1	40,8	40,5		16,2%	15,4%
32	G8171T	33,3	43,2	50,7		29,7%	52,3%	32	G8171T	35,1	36,7	40,2		4,6%	14,5%
33	D4546E	32,7	52,1	55,6		59,3%	70,0%	33	D4546E	33,4	39,3	45,1		17,7%	35,0%
34	S8025S	37,7	45,4	45,8		20,4%	21,5%	34	S8025S	35,9	36,3	38,2		1,1%	6,4%
35	B4706F	35,1	44,3	47,5	26,2%	35,3%	35	B4706F	36,0	40,8	42,3	13,3%	17,5%		
Mean		34,3	43,9	48,1	28,5%	40,5%	Mean		34,0	37,5	39,1	10,4%	15,0%		
SE		0,6	1,0	0,9	-1,1%	14,6%	SE		0,5	0,8	0,8	-6,6%	-1,3%		
t test vs. T0		---	0,000	0,000	59,3%	70,0%	t test vs. T0		---	0,000	0,000	43,5%	37,3%		
t test act. vs. pl.		---	---	---	0,000	0,000									

Legend: SE Standard Error; pl. placebo product



GRAPH 2 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant increase vs T0 of skin moisturization by +28.5% at T7 and by +40.5% at T28 is recorded after tested product use; an increase of the monitored parameter is also recorded after placebo product use, respectively by +10.4% at T7 and by +15.0% at T28.

The variations recorded with tested product are statistically higher than those recorded with placebo product.



SKIN RADIANCE/BRIGHTNESS – GLOSS PARAMETER


TABLES 3a,b The tables below show the obtained data for each volunteer at each experimental time. Data are expressed in arbitrary units (a.u.).

TESTED PRODUCT					PLACEBO PRODUCT												
no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28	no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28		
01	R4596I	8,80	10,81	15,97		22,8%	81,5%	01	R4596I	9,04	10,66	9,87		17,9%	9,2%		
02	F7470E	8,99	11,05	14,92		22,9%	66,0%	02	F7470E	9,01	9,76	10,26		8,3%	13,9%		
03	B4852D	9,02	12,68	12,62		40,6%	39,9%	03	B4852D	8,49	11,19	10,05		31,8%	18,4%		
04	D8536C	9,33	10,39	10,93		11,4%	17,1%	04	D8536C	11,99	10,21	10,66		-14,8%	-11,1%		
05	S4702R	8,89	11,70	11,89		31,6%	33,7%	05	S4702R	8,29	11,10	10,47		33,9%	26,3%		
06	M7206C	8,12	9,92	9,90		22,2%	21,9%	06	M7206C	7,41	8,94	8,35		20,6%	12,7%		
07	P6503V	11,74	12,55	12,80		6,9%	9,0%	07	P6503V	11,16	11,44	10,89		2,5%	-2,4%		
08	B3231G	10,50	10,00	10,30		-4,8%	-1,9%	08	B3231G	10,48	10,51	9,90		0,3%	-5,5%		
09	S3327S	10,46	12,76	15,03		22,0%	43,7%	09	S3327S	10,00	12,78	12,31		27,8%	23,1%		
10	G4137M	8,73	9,47	9,77		8,5%	11,9%	10	G4137M	7,76	8,80	8,63		13,4%	11,2%		
11	R0471E	7,59	11,44	12,79		50,7%	68,5%	11	R0471E	8,82	9,01	9,01		2,2%	2,2%		
12	S6987S	7,18	13,37	13,88		86,2%	93,3%	12	S6987S	7,78	12,23	12,67		57,2%	62,9%		
13	C7481S	8,09	12,99	14,39		60,6%	77,9%	13	C7481S	8,46	11,84	13,36		40,0%	57,9%		
14	M4081A	10,42	10,40	12,02		-0,2%	15,4%	14	M4081A	9,36	9,40	10,32		0,4%	10,3%		
15	M1308V	9,49	10,79	11,11		13,7%	17,1%	15	M1308V	9,52	10,63	9,30		11,7%	-2,3%		
16	M3862R	7,07	11,80	12,41		66,9%	75,5%	16	M3862R	7,26	11,97	10,58		64,9%	45,7%		
17	S1995S	7,45	13,78	13,76		85,0%	84,7%	17	S1995S	7,65	10,20	9,31		33,3%	21,7%		
18	B4239N	8,35	11,85	11,34		41,9%	35,8%	18	B4239N	9,87	11,47	10,22		16,2%	3,5%		
19	C0947V	10,62	9,59	12,78		-9,7%	20,3%	19	C0947V	11,36	10,00	10,78		-12,0%	-5,1%		
20	C1227F	7,89	12,19	12,71		54,5%	61,1%	20	C1227F	8,34	9,50	10,08		13,9%	20,9%		
21	L2381A	10,18	10,29	13,33		1,1%	30,9%	21	L2381A	10,50	10,39	10,00		-1,0%	-4,8%		
22	G1487B	9,97	13,50	15,66		35,4%	57,1%	22	G1487B	10,11	10,52	10,11		4,1%	0,0%		
23	C4251L	9,59	13,05	14,73		36,1%	53,6%	23	C4251L	9,28	10,73	11,32		15,6%	22,0%		
24	V8704B	9,46	14,96	15,64		58,1%	65,3%	24	V8704B	10,71	12,57	12,45		17,4%	16,2%		
25	G5429D	9,01	11,36	14,70		26,1%	63,2%	25	G5429D	8,86	9,44	11,17		6,5%	26,1%		
26	G5068M	13,00	13,50	13,62		3,8%	4,8%	26	G5068M	13,43	13,10	12,37		-2,5%	-7,9%		
27	Z7572C	10,91	13,60	14,85		24,7%	36,1%	27	Z7572C	10,07	10,83	10,00		7,5%	-0,7%		
28	R7603F	8,66	8,82	13,92		1,8%	60,7%	28	R7603F	9,00	8,62	8,89		-4,2%	-1,2%		
29	P7628M	11,72	14,72	15,03		25,6%	28,2%	29	P7628M	11,39	10,45	11,50		-8,3%	1,0%		
30	C1201L	11,41	10,70	13,28		-6,2%	16,4%	30	C1201L	10,31	10,29	12,45		-0,2%	20,8%		
31	P5338A	11,18	12,00	14,55		7,3%	30,1%	31	P5338A	11,70	10,07	10,12		-13,9%	-13,5%		
32	G8171T	8,90	9,11	10,55		2,4%	18,5%	32	G8171T	8,45	8,11	8,64		-4,0%	2,2%		
33	D4546E	7,10	14,50	14,02		104,2%	97,5%	33	D4546E	7,61	9,62	10,50		26,4%	38,0%		
34	S8025S	8,75	14,70	15,45		68,0%	76,6%	34	S8025S	7,80	13,15	10,92		68,6%	40,0%		
35	B4706F	12,43	12,88	15,50	3,6%	24,7%	35	B4706F	12,43	12,88	12,79	3,6%	2,9%				
Mean		9,46	11,92	13,32	29,3%		43,9%	Mean		9,53	10,64	10,58	13,9%		13,0%		
SE		0,26	0,29	0,30	Min		-9,7%	-1,9%	SE		0,26	0,22	0,22	Min		-14,8%	-13,5%
t test vs. T0		---	0,000	0,000	Max		104,2%	97,5%	t test vs. T0		---	0,001	0,000	Max		68,6%	62,9%

Legend: SE Standard Error; pl. placebo product



GRAPH 3 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant increase vs T0 of gloss parameter by +29.3% at T7 and by +43.9% at T28 is recorded after tested product use; an increase of the monitored parameter is also recorded after placebo product use, respectively by +13.9% at T7 and by +13.0% at T28.

The variations recorded with tested product are statistically higher than those recorded with placebo product.

An increase of this parameter indicates an improvement of skin radiance/brightness.



SKIN FIRMNESS – R0 PARAMETER

TABLES 4a,b The tables below show the obtained data for each volunteer at each experimental time. Data are expressed as Uf.

TESTED PRODUCT

no.	Vol. ID	T0	T7	T28		T7	T28
01	R4596I	0,337	0,327	0,332		-3,0%	-1,5%
02	F7470E	0,351	0,336	0,303		-4,3%	-13,7%
03	B4852D	0,441	0,413	0,408		-6,3%	-7,5%
04	D8536C	0,492	0,402	0,386		-18,3%	-21,5%
05	S4702R	0,377	0,369	0,359		-2,1%	-4,8%
06	M7206C	0,477	0,432	0,405		-9,4%	-15,1%
07	P6503V	0,327	0,306	0,323		-6,4%	-1,2%
08	B3231G	0,415	0,395	0,305		-4,8%	-26,5%
09	S3327S	0,455	0,450	0,421		-1,1%	-7,5%
10	G4137M	0,442	0,415	0,388		-6,1%	-12,2%
11	R0471E	0,330	0,330	0,327		0,0%	-0,9%
12	S6987S	0,373	0,314	0,298		-15,8%	-20,1%
13	C7481S	0,430	0,448	0,415		4,2%	-3,5%
14	M4081A	0,486	0,455	0,442		-6,4%	-9,1%
15	M1308V	0,426	0,414	0,402		-2,8%	-5,6%
16	M3862R	0,442	0,431	0,425		-2,5%	-3,8%
17	S1995S	0,402	0,373	0,344		-7,2%	-14,4%
18	B4239N	0,431	0,431	0,404		0,0%	-6,3%
19	C0947V	0,338	0,313	0,307		-7,4%	-9,2%
20	C1227F	0,439	0,373	0,373		-15,0%	-15,0%
21	L2381A	0,462	0,421	0,414		-8,9%	-10,4%
22	G1487B	0,356	0,332	0,302		-6,7%	-15,2%
23	C4251L	0,325	0,300	0,284		-7,7%	-12,6%
24	V8704B	0,344	0,330	0,326		-4,1%	-5,2%
25	G5429D	0,391	0,396	0,380		1,3%	-2,8%
26	G5068M	0,314	0,308	0,270		-1,9%	-14,0%
27	Z7572C	0,340	0,347	0,335		2,1%	-1,5%
28	R7603F	0,382	0,377	0,344		-1,3%	-9,9%
29	P7628M	0,326	0,286	0,282		-12,3%	-13,5%
30	C1201L	0,372	0,362	0,356		-2,7%	-4,3%
31	P5338A	0,357	0,334	0,330		-6,4%	-7,6%
32	G8171T	0,362	0,314	0,312		-13,3%	-13,8%
33	D4546E	0,431	0,416	0,402		-3,5%	-6,7%
34	S8025S	0,366	0,318	0,312		-13,1%	-14,8%
35	B4706F	0,440	0,417	0,371		-5,2%	-15,7%
	Mean	0,394	0,371	0,354		-5,7%	-9,9%
	SE	0,009	0,009	0,008		Max	-18,3%
	t test vs. T0	---	0,000	0,000		Min	4,2%
	t test act. vs. pl.	---	---	---			0,000


PLACEBO PRODUCT

no.	Vol. ID	T0	T7	T28		T7	T28
01	R4596I	0,379	0,371	0,358		-2,1%	-5,5%
02	F7470E	0,379	0,375	0,393		-1,1%	3,7%
03	B4852D	0,478	0,467	0,427		-2,3%	-10,7%
04	D8536C	0,472	0,429	0,453		-9,1%	-4,0%
05	S4702R	0,393	0,363	0,364		-7,6%	-7,4%
06	M7206C	0,493	0,468	0,460		-5,1%	-6,7%
07	P6503V	0,330	0,343	0,343		3,9%	3,9%
08	B3231G	0,377	0,377	0,365		0,0%	-3,2%
09	S3327S	0,446	0,446	0,451		0,0%	1,1%
10	G4137M	0,476	0,468	0,440		-1,7%	-7,6%
11	R0471E	0,346	0,353	0,408		2,0%	17,9%
12	S6987S	0,324	0,338	0,357		4,3%	10,2%
13	C7481S	0,412	0,425	0,425		3,2%	3,2%
14	M4081A	0,480	0,499	0,480		4,0%	0,0%
15	M1308V	0,451	0,453	0,450		0,4%	-0,2%
16	M3862R	0,431	0,417	0,418		-3,2%	-3,0%
17	S1995S	0,400	0,408	0,409		2,0%	2,2%
18	B4239N	0,390	0,399	0,404		2,3%	3,6%
19	C0947V	0,327	0,353	0,334		8,0%	2,1%
20	C1227F	0,425	0,434	0,422		2,1%	-0,7%
21	L2381A	0,419	0,427	0,422		1,9%	0,7%
22	G1487B	0,357	0,363	0,343		1,7%	-3,9%
23	C4251L	0,379	0,403	0,428		6,3%	12,9%
24	V8704B	0,364	0,346	0,336		-4,9%	-7,7%
25	G5429D	0,366	0,365	0,356		-0,3%	-2,7%
26	G5068M	0,357	0,362	0,354		1,4%	-0,8%
27	Z7572C	0,346	0,378	0,404		9,2%	16,8%
28	R7603F	0,339	0,399	0,408		17,7%	20,4%
29	P7628M	0,303	0,348	0,338		14,9%	11,6%
30	C1201L	0,344	0,344	0,374		0,0%	8,7%
31	P5338A	0,369	0,421	0,424		14,1%	14,9%
32	G8171T	0,366	0,377	0,346		3,0%	-5,5%
33	D4546E	0,427	0,433	0,447		1,4%	4,7%
34	S8025S	0,344	0,346	0,344		0,6%	0,0%
35	B4706F	0,404	0,430	0,423		6,4%	4,7%
	Mean	0,391	0,398	0,397		2,1%	2,1%
	SE	0,009	0,007	0,007		Max	-9,1%
	t test vs. T0	---	0,070	0,225		Min	17,7%
							20,4%

Legend: SE Standard Error; pl. placebo product



GRAPH 4 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant decrease vs T0 of R0 parameter by -5.7% at T7 and by -9.9% at T28 is recorded after tested product use; no significant variation of the monitored parameter is recorded after placebo product use.

The variations recorded with tested product are statistically higher compared to placebo product. A decrease of R0 parameter is related to an improvement of skin firmness.



SKIN ELASTICITY – R2 PARAMETER


TABLES 5a,b The tables below show the obtained data for each volunteer at each experimental time. Data are expressed as Ua/Uf.

TESTED PRODUCT						PLACEBO PRODUCT					
no.	Vol. ID	T0	T7	T28		no.	Vol. ID	T0	T7	T28	
01	R4596I	0,7893	0,7899	0,8095	Variation vs. T0	01	R4596I	0,7203	0,7252	0,7273	Variation vs. T0
02	F7470E	0,6749	0,6945	0,7505		02	F7470E	0,6846	0,6543	0,6774	
03	B4852D	0,7279	0,7923	0,8114		03	B4852D	0,7092	0,7093	0,6960	
04	D8536C	0,6323	0,7110	0,7972		04	D8536C	0,5826	0,6413	0,6312	
05	S4702R	0,6135	0,6769	0,6789		05	S4702R	0,6876	0,6924	0,6794	
06	M7206C	0,6946	0,7239	0,7316		06	M7206C	0,6911	0,6960	0,6958	
07	P6503V	0,7012	0,7864	0,7585		07	P6503V	0,7030	0,7143	0,7169	
08	B3231G	0,6031	0,6738	0,6859		08	B3231G	0,6072	0,6000	0,6450	
09	S3327S	0,6670	0,7000	0,7411		09	S3327S	0,6233	0,6545	0,6367	
10	G4137M	0,6640	0,6667	0,7639		10	G4137M	0,6681	0,6680	0,6542	
11	R0471E	0,6913	0,7035	0,7919		11	R0471E	0,6317	0,6409	0,6093	
12	S6987S	0,7025	0,7850	0,8554		12	S6987S	0,6927	0,7026	0,7160	
13	C7481S	0,7472	0,7567	0,7739		13	C7481S	0,7762	0,7860	0,7746	
14	M4081A	0,6226	0,6817	0,6868		14	M4081A	0,6399	0,6243	0,6352	
15	M1308V	0,6491	0,6452	0,6816		15	M1308V	0,6866	0,6355	0,6730	
16	M3862R	0,6385	0,6662	0,7298		16	M3862R	0,6555	0,6513	0,6563	
17	S1995S	0,6090	0,6802	0,7418		17	S1995S	0,6263	0,6273	0,6727	
18	B4239N	0,6069	0,6229	0,6732		18	B4239N	0,6310	0,6085	0,6212	
19	C0947V	0,7929	0,7891	0,8377		19	C0947V	0,7702	0,7365	0,7616	
20	C1227F	0,6234	0,6593	0,6997		20	C1227F	0,6180	0,6460	0,6357	
21	L2381A	0,5725	0,6602	0,6610		21	L2381A	0,6241	0,6643	0,6609	
22	G1487B	0,6180	0,7457	0,7484		22	G1487B	0,6077	0,6214	0,6851	
23	C4251L	0,8000	0,8300	0,8654		23	C4251L	0,7546	0,7246	0,7992	
24	V8704B	0,6984	0,7413	0,7817		24	V8704B	0,6780	0,6846	0,7240	
25	G5429D	0,7429	0,7449	0,8000		25	G5429D	0,7444	0,7313	0,7399	
26	G5068M	0,8227	0,8389	0,8872		26	G5068M	0,8123	0,8072	0,8147	
27	Z7572C	0,6324	0,6175	0,6701		27	Z7572C	0,6035	0,5856	0,5895	
28	R7603F	0,6582	0,7136	0,7645		28	R7603F	0,6353	0,6949	0,7240	
29	P7628M	0,7975	0,8133	0,8089		29	P7628M	0,7884	0,7580	0,7444	
30	C1201L	0,5442	0,6951	0,7171		30	C1201L	0,5470	0,6122	0,6658	
31	P5338A	0,7200	0,7735	0,7694		31	P5338A	0,7104	0,7227	0,7182	
32	G8171T	0,8177	0,8809	0,8942		32	G8171T	0,7669	0,7520	0,8184	
33	D4546E	0,7770	0,8510	0,8599		33	D4546E	0,7501	0,7928	0,7984	
34	S8025S	0,6015	0,6179	0,6881		34	S8025S	0,6080	0,6050	0,6066	
35	B4706F	0,6583	0,6634	0,7092		35	B4706F	0,6450	0,6199	0,6310	
Mean		0,6832	0,7255	0,7607		Mean		0,6766	0,6797	0,6924	
SE		0,0127	0,0119	0,0111	Min	SE		0,0110	0,0100	0,0105	Min
t test vs. T0		---	0,000	0,000	Max	t test vs. T0		---	0,503	0,010	Max
t test act. vs. pl.		---	---	---							

Legend: SE Standard Error; pl. placebo product



GRAPH 5 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant increase vs T0 of R2 parameter by +6.5% at T7 and by +11.8% at T28 is recorded after tested product use; a significant variation of the monitored parameter is also recorded after placebo product use at T28 by +2.6%.

The variations recorded with tested product are statistically higher than those recorded with placebo product.

An increase of R2 parameter is related to an improvement of skin elasticity.



SKIN PROFILOMETRY: SKIN SMOOTHNESS - Ra PARAMETER


TABLES 6a,b The tables below show the data obtained for each subject participating in the study. Data are expressed as μm .

TESTED PRODUCT						PLACEBO PRODUCT					
no.	Vol. ID	T0	T7	T28		no.	Vol. ID	T0	T7	T28	
01	R4596I	22,895	22,794	20,598	Variation vs. T0	01	R4596I	30,895	29,872	31,365	Variation vs. T0
02	F7470E	25,924	26,891	27,342		02	F7470E	21,109	23,332	23,782	
03	B4852D	28,659	27,745	25,209		03	B4852D	23,536	28,305	26,939	
04	D8536C	38,498	25,733	24,835		04	D8536C	28,748	20,691	24,671	
05	S4702R	26,110	21,599	26,030		05	S4702R	26,500	26,365	29,489	
06	M7206C	29,687	29,265	33,916		06	M7206C	30,091	29,381	33,906	
07	P6503V	26,506	23,874	23,074		07	P6503V	23,560	25,984	23,227	
08	B3231G	23,194	23,511	27,155		08	B3231G	38,189	41,775	53,870	
09	S3327S	23,929	25,429	22,534		09	S3327S	25,871	25,871	27,442	
10	G4137M	18,349	22,801	21,814		10	G4137M	18,947	18,157	22,249	
11	R0471E	26,254	25,935	21,567		11	R0471E	27,414	24,013	27,424	
12	S6987S	25,841	28,188	27,925		12	S6987S	23,635	25,818	24,813	
13	C7481S	22,205	22,918	20,335		13	C7481S	27,323	27,600	36,400	
14	M4081A	23,823	24,951	20,859		14	M4081A	28,616	27,878	27,759	
15	M1308V	22,036	22,426	24,061		15	M1308V	21,673	26,160	23,857	
16	M3862R	27,256	26,501	25,779		16	M3862R	25,901	30,670	29,244	
17	S1995S	35,852	34,104	31,751		17	S1995S	21,916	26,731	22,510	
18	B4239N	26,315	28,170	30,703		18	B4239N	24,829	28,916	24,905	
19	C0947V	22,397	19,392	21,179		19	C0947V	18,258	16,143	17,033	
20	C1227F	25,905	24,846	17,168		20	C1227F	28,983	26,359	25,068	
21	L2381A	27,610	24,635	27,450		21	L2381A	32,407	29,502	31,107	
22	G1487B	20,592	24,168	22,235		22	G1487B	24,965	25,111	26,161	
23	C4251L	19,159	18,349	16,743		23	C4251L	23,551	19,613	20,958	
24	V8704B	24,733	22,503	22,068		24	V8704B	23,083	22,093	20,942	
25	G5429D	21,299	21,829	20,421		25	G5429D	25,668	23,699	22,177	
26	G5068M	20,506	20,005	20,417		26	G5068M	24,490	26,280	25,723	
27	Z7572C	30,134	29,155	26,685		27	Z7572C	29,080	25,594	22,253	
28	R7603F	27,928	25,018	22,466		28	R7603F	30,752	27,954	24,313	
29	P7628M	19,761	24,758	20,185		29	P7628M	18,356	21,999	18,758	
30	C1201L	38,474	40,704	26,542		30	C1201L	26,633	28,854	34,067	
31	P5338A	30,537	30,362	31,083		31	P5338A	28,207	31,129	34,073	
32	G8171T	29,099	30,314	26,816		32	G8171T	33,077	33,353	33,837	
33	D4546E	41,147	34,319	28,737		33	D4546E	27,273	29,521	27,301	
34	S8025S	24,434	26,225	23,948		34	S8025S	25,366	26,015	22,107	
35	B4706F	36,659	38,526	44,275		35	B4706F	26,295	27,179	32,036	
Mean		26,677	26,227	24,969		Mean		26,148	26,512	27,193	
SE		0,967	0,835	0,888	Max	SE		0,716	0,769	1,120	Max
t test vs. T0	---	---	0,415	0,037	Min	t test vs. T0	---	---	0,478	0,166	Min
t test act. vs. pl.	---	---	---	---							

Legend: SE Standard Error; pl. placebo product



GRAPH 6 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** p<0.001 vs T0; ** p<0.01 vs T0; * p<0.05 vs T0.



COMMENT

As it is possible to notice, a statistically significant decrease vs T0 of Ra parameter by -5.1% at T28 is recorded after tested product use while no significant variation of the monitored parameter was recorded at T7 for active product and at T7 and T28 with placebo product.

The variation recorded at T28 with tested product is statistically greater than that recorded with placebo product.

A decrease of Ra parameter indicates an improvement of skin smoothness and for marketing purposes obtained Variations can be expressed in absolute values as an improvement of skin smoothness.



SKIN PROFILOMETRY: SKIN ROUGHNESS – Rz PARAMETER


TABLES 7a,b The tables below show the data obtained for each subject participating in the study. Data are expressed as μm .

TESTED PRODUCT						PLACEBO PRODUCT										
no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28	Variation vs. T0	no.	Vol. ID	T0	T7	T28	Variation vs. T0	T7	T28
01	R4596I	123,23	122,75	114,28		-0,4%	-7,3%		01	R4596I	174,74	162,94	170,19		-6,8%	-2,6%
02	F7470E	149,89	153,28	148,84		2,3%	-0,7%		02	F7470E	118,83	134,86	133,51		13,5%	12,4%
03	B4852D	162,70	159,24	139,13		-2,1%	-14,5%		03	B4852D	133,99	161,21	153,32		20,3%	14,4%
04	D8536C	232,01	149,23	144,43		-35,7%	-37,7%		04	D8536C	191,24	115,56	132,98		-39,6%	-30,5%
05	S4702R	144,42	110,40	143,42		-23,6%	-0,7%		05	S4702R	144,88	148,82	165,70		2,7%	14,4%
06	M7206C	174,47	166,00	190,90		-4,9%	9,4%		06	M7206C	175,50	164,67	196,92		-6,2%	12,2%
07	P6503V	141,49	137,73	123,94		-2,7%	-12,4%		07	P6503V	131,31	144,09	130,19		9,7%	-0,9%
08	B3231G	119,62	117,63	140,05		-1,7%	17,1%		08	B3231G	185,15	227,00	255,42		22,6%	38,0%
09	S3327S	130,54	136,32	119,56		4,4%	-8,4%		09	S3327S	141,90	145,78	152,17		2,7%	7,2%
10	G4137M	95,15	118,15	112,38		24,2%	18,1%		10	G4137M	101,61	98,39	118,98		-3,2%	17,1%
11	R0471E	147,72	145,82	124,54		-1,3%	-15,7%		11	R0471E	156,52	136,28	158,29		-12,9%	1,1%
12	S6987S	143,86	166,23	157,88		15,5%	9,7%		12	S6987S	130,03	146,61	139,12		12,8%	7,0%
13	C7481S	124,80	129,14	113,07		3,5%	-9,4%		13	C7481S	157,53	161,89	204,61		2,8%	29,9%
14	M4081A	130,73	145,15	111,40		11,0%	-14,8%		14	M4081A	163,22	146,89	148,10		-10,0%	-9,3%
15	M1308V	118,46	121,65	129,09		2,7%	9,0%		15	M1308V	117,88	140,47	129,76		19,2%	10,1%
16	M3862R	155,58	154,20	148,67		-0,9%	-4,4%		16	M3862R	141,50	171,66	168,16		21,3%	18,8%
17	S1995S	195,65	184,68	170,62		-5,6%	-12,8%		17	S1995S	118,55	146,11	122,39		23,2%	3,2%
18	B4239N	135,38	147,84	173,61		9,2%	28,2%		18	B4239N	133,77	155,76	135,83		16,4%	1,5%
19	C0947V	130,40	112,02	120,89		-14,1%	-7,3%		19	C0947V	95,78	82,55	87,98		-13,8%	-8,1%
20	C1227F	138,92	137,05	96,96		-1,3%	-30,2%		20	C1227F	155,32	145,28	136,74		-6,5%	-12,0%
21	L2381A	147,23	133,44	148,13		-9,4%	0,6%		21	L2381A	182,27	174,32	177,71		-4,4%	-2,5%
22	G1487B	115,61	137,14	125,96		18,6%	9,0%		22	G1487B	133,58	141,01	148,07		5,6%	10,8%
23	C4251L	107,07	100,37	95,42		-6,3%	-10,9%		23	C4251L	135,82	112,17	124,12		-17,4%	-8,6%
24	V8704B	138,61	124,73	124,38		-10,0%	-10,3%		24	V8704B	133,99	120,01	118,31		-10,4%	-11,7%
25	G5429D	116,95	130,27	110,90		11,4%	-5,2%		25	G5429D	135,65	129,55	116,54		-4,5%	-14,1%
26	G5068M	114,49	112,04	115,25		-2,1%	0,7%		26	G5068M	132,62	152,27	136,23		14,8%	2,7%
27	Z7572C	171,91	165,46	146,52		-3,8%	-14,8%		27	Z7572C	151,61	140,57	123,70		-7,3%	-18,4%
28	R7603F	160,50	148,61	129,55		-7,4%	-19,3%		28	R7603F	165,94	156,36	133,10		-5,8%	-19,8%
29	P7628M	108,55	136,46	108,81		25,7%	0,2%		29	P7628M	98,83	120,75	99,39		22,2%	0,6%
30	C1201L	293,96	316,88	220,04		7,8%	-25,1%		30	C1201L	146,63	156,89	203,61		7,0%	38,9%
31	P5338A	134,71	133,84	138,72		-0,6%	3,0%		31	P5338A	159,34	180,18	197,19		13,1%	23,8%
32	G8171T	168,70	167,83	145,32		-0,5%	-13,9%		32	G8171T	175,06	177,70	179,89		1,5%	2,8%
33	D4546E	240,32	185,92	165,95		-22,6%	-30,9%		33	D4546E	161,15	164,17	148,38		1,9%	-7,9%
34	S8025S	138,33	148,63	140,78		7,4%	1,8%		34	S8025S	154,07	152,03	130,42		-1,3%	-15,4%
35	B4706F	170,09	178,16	214,18	4,7%	25,9%	35	B4706F	142,01	144,13	176,46	1,5%	24,3%			
Mean		149,20	146,69	138,67		-0,2%	-5,0%		Mean		145,08	147,40	150,10		2,4%	3,7%
SE		6,82	6,17	4,94	Max	-35,7%	-37,7%		SE		4,04	4,32	5,74	Max	-39,6%	-30,5%
t test vs. T0		---	0,492	0,033	Min	25,7%	28,2%		t test vs. T0		---	0,521	0,258	Min	23,2%	38,9%
st act. vs. 01759.20		---	---	---		0,268	0,003									

Legend: SE Standard Error; pl. placebo product



GRAPH 7 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant decrease vs T0 of Rz parameter by -5.0% at T28 is recorded after active product use while no significant variation of the monitored parameter was recorded at T7 for tested product and at T7 and T28 with placebo product.

The variation recorded at T28 with tested product is statistically greater than that recorded with placebo product.

A decrease of Rz parameter indicates an improvement of skin roughness.



TRANSEPIDERMAL WATER LOSS


TABLES 8a,b The tables below show the data obtained for each subject participating in the study. Data are expressed as g/h/m².

TESTED PRODUCT						PLACEBO PRODUCT					
no.	Vol. ID	T0	T7	T28		no.	Vol. ID	T0	T7	T28	
01	R4596I	14,2	13,5	10,6		01	R4596I	13,7	13,4	9,8	
02	F7470E	7,9	8,5	8,1		02	F7470E	8,1	9,4	9,3	
03	B4852D	9,0	11,5	11,2		03	B4852D	9,1	10,3	9,4	
04	D8536C	8,6	9,0	7,3		04	D8536C	8,5	10,7	9,9	
05	S4702R	7,7	9,9	8,1		05	S4702R	7,6	9,6	9,9	
06	M7206C	10,4	9,2	9,9		06	M7206C	10,9	10,2	10,3	
07	P6503V	6,9	7,0	8,8		07	P6503V	7,8	8,2	9,0	
08	B3231G	12,5	11,6	8,9		08	B3231G	11,5	11,2	9,3	
09	S3327S	11,5	11,7	11,6		09	S3327S	11,3	12,5	10,9	
10	G4137M	10,3	9,2	9,5		10	G4137M	10,6	10,8	10,1	
11	R0471E	9,4	11,1	11,6		11	R0471E	10,4	11,5	10,4	
12	S6987S	12,3	9,1	10,3		12	S6987S	12,4	10,3	10,8	
13	C7481S	10,0	7,0	8,6		13	C7481S	9,5	8,6	9,3	
14	M4081A	12,4	10,4	10,0		14	M4081A	11,6	11,4	11,3	
15	M1308V	10,1	10,2	8,4		15	M1308V	9,6	10,8	7,6	
16	M3862R	10,9	10,4	9,5		16	M3862R	11,6	10,4	10,7	
17	S1995S	7,5	8,3	8,8		17	S1995S	8,0	9,8	8,3	
18	B4239N	8,8	8,9	8,0		18	B4239N	10,6	9,4	9,1	
19	C0947V	9,2	9,3	8,0		19	C0947V	8,5	10,7	8,6	
20	C1227F	11,5	9,2	9,6		20	C1227F	12,7	11,3	9,7	
21	L2381A	11,9	11,5	11,4		21	L2381A	10,8	10,1	10,6	
22	G1487B	9,0	7,8	12,1		22	G1487B	10,2	8,4	9,5	
23	C4251L	11,7	9,2	9,7		23	C4251L	10,2	10,7	8,4	
24	V8704B	11,0	9,8	10,6		24	V8704B	10,5	11,7	9,3	
25	G5429D	7,4	7,4	7,2		25	G5429D	8,1	8,7	7,5	
26	G5068M	8,8	7,7	7,3		26	G5068M	10,0	9,7	8,8	
27	Z7572C	13,5	10,4	9,5		27	Z7572C	13,1	9,5	9,3	
28	R7603F	9,6	9,4	9,9		28	R7603F	10,0	11,1	9,1	
29	P7628M	9,7	9,6	9,1		29	P7628M	8,6	9,3	9,0	
30	C1201L	11,7	11,0	12,0		30	C1201L	11,3	10,5	10,6	
31	P5338A	11,1	10,6	9,2		31	P5338A	10,4	9,9	8,2	
32	G8171T	10,0	8,0	8,6		32	G8171T	9,1	8,5	8,2	
33	D4546E	9,0	10,9	10,5		33	D4546E	8,8	10,2	10,8	
34	S8025S	7,7	7,1	8,2		34	S8025S	10,7	9,3	8,4	
35	B4706F	10,5	9,6	9,6		35	B4706F	10,7	12,4	8,9	
Mean		10,1	9,6	9,5		Mean		10,2	10,3	9,4	
SE		0,3	0,3	0,2		SE		0,3	0,2	0,2	
t test vs. T0		---	0,032	0,032		t test vs. T0		---	0,623	0,004	
t test act. vs. pl.		---	---	---							
Max						Max					
Min						Min					
0,001						0,001					
0,574						0,574					

Legend: SE Standard Error; pl. placebo product



GRAPH 8 The graph shows the mean data obtained at each experimental time for the analysed parameter. Data are expressed as mean $\pm$ SE. Above the error bar the intragroup (vs T0, black asterisks) and intergroup (vs placebo, red asterisks) statistical analysis are reported as follow: *** $p < 0.001$ vs T0; ** $p < 0.01$ vs T0; * $p < 0.05$ vs T0.



COMMENT

As it is possible to notice, a statistically significant decrease vs T0 of transepidermal water loss by -4.0% at T7 and by -4.4% at T28 is recorded after tested product use; a decrease of the monitored parameter is also recorded after placebo product use, respectively by -5.8%.

The variation recorded with tested product at T7 is statistically greater than that recorded with placebo product while no significant difference between groups is observed at T28.

A decrease of transepidermal water loss indicates an improvement of skin barrier condition.



SELF-ASSESSMENT QUESTIONNAIRE

TABLES 9a,b The tables summarize the results of the self-assessment questionnaire filled in by the subjects 12 hours after the first product application. Results are calculated as percentage (%) of subjects who assigned a judgment (among those proposed).

TESTED PRODUCT

GLOBAL APPRECIATION OF THE PRODUCT						
No.	Items	Very pleasant	Pleasant	Neither pleasant nor unpleasant	Unpleasant	Very unpleasant
01	What do you think about the product aspect?	51,4%	42,9%	5,7%	0,0%	0,0%
02	What do you think about the product texture?	60,0%	40,0%	0,0%	0,0%	0,0%
03	What do you think about the product fragrance?	25,7%	54,3%	20,0%	0,0%	0,0%
04	What do you think about product spreadability?	40,0%	51,4%	8,6%	0,0%	0,0%
No.	Items	Very good	Good	Not good	Bad	Positive answers
05	What do you think about product penetration?	45,7%	51,4%	2,9%	0,0%	--
No.	Items	Silky	Soft	Sticky	Oily	Positive answers
06	What is the after feel effect on the skin?	48,6%	42,9%	8,6%	0,0%	--
No.	Items	Very good	Good	Not good	Bad	Positive answers
07	What is your overall appreciation of this product?	42,9%	57,1%	0,0%	0,0%	--
APPRECIATION OF IMMEDIATE PRODUCT PERFORMANCE						
No.	Items	Yes, absolutely	Yes, mildly	Yes, slightly	Not	Positive answers
08	Immediately after the application, does the skin appear more nourished and hydrated?	48,6%	34,3%	17,1%	0,0%	--
09	After application, does the skin appear softer?	54,3%	40,0%	5,7%	0,0%	--
APPRECIATION OF PRODUCT PERFORMANCE 12 HOURS AFTER APPLICATION (MORNING AFTER)						
No.	Items	Yes, absolutely	Yes, mildly	Yes, slightly	Not	Positive answers
10	12 hours after application, have you noticed that skin dryness and tightening sensation are improved?	40,0%	40,0%	8,6%	11,4%	--
11	12 hours after application, have you noticed that signs of fatigue are improved, and skin looks more rested / revived?	20,0%	42,9%	17,1%	20,0%	--

Legend

Positive answers → % of subjects who gave positive judgement as “very pleasant” or “pleasant” or “very good” or “good”, “silky” or “soft”, “yes, absolutely” or “yes, mildly”. The percentages are rounded off, this is why the sum of these percentages may be different from 100%.



PLACEBO PRODUCT

GLOBAL APPRECIATION OF THE PRODUCT							
No.	Items	Very pleasant	Pleasant	Neither pleasant nor unpleasant	Unpleasant	Very unpleasant	Positive answers
01	What do you think about the product aspect?	45,7%	51,4%	2,9%	0,0%	0,0%	97,1%
02	What do you think about the product texture?	51,4%	48,6%	0,0%	0,0%	0,0%	100,0%
03	What do you think about the product fragrance?	20,0%	57,1%	22,9%	0,0%	0,0%	77,1%
04	What do you think about product spreadability?	48,6%	42,9%	8,6%	0,0%	0,0%	91,4%
No.	Items	Very good	Good	Not good	Bad		Positive answers
05	What do you think about product penetration?	34,3%	60,0%	5,7%	0,0%	--	94,3%
No.	Items	Silky	Soft	Sticky	Oily		Positive answers
06	What is the after feel effect on the skin?	42,9%	45,7%	5,7%	5,7%	--	88,6%
No.	Items	Very good	Good	Not good	Bad		Positive answers
07	What is your overall appreciation of this product?	34,3%	60,0%	5,7%	0,0%	--	94,3%
APPRECIATION OF IMMEDIATE PRODUCT PERFORMANCE							
No.	Items	Yes, absolutely	Yes, mildly	Yes, slightly	Not		Positive answers
08	Immediately after the application, does the skin appear more nourished and hydrated?	42,9%	45,7%	11,4%	0,0%	--	100,0%
09	After application, does the skin appear softer?	51,4%	37,1%	11,4%	0,0%	--	100,0%
APPRECIATION OF PRODUCT PERFORMANCE 12 HOURS AFTER APPLICATION (MORNING AFTER)							
No.	Items	Yes, absolutely	Yes, mildly	Yes, slightly	Not		Positive answers
10	12 hours after application, have you noticed that skin dryness and tightening sensation are improved?	42,9%	34,3%	11,4%	11,4%	--	88,6%
11	12 hours after application, have you noticed that signs of fatigue are improved, and skin looks more rested / revived?	14,3%	54,3%	17,1%	14,3%	--	85,7%

Legend

Positive answers → % of subjects who gave positive judgement as “very pleasant” or “pleasant” or “very good” or “good”, “silky” or “soft”, “yes, absolutely” or “yes, mildly”. The percentages are rounded off, this is why the sum of these percentages may be different from 100%.



TABLES 10a,b The tables summarize the results of the self-assessment questionnaire filled in by the subjects at the end of the study. Results are calculated as percentage (%) of subjects who assigned a judgment (among those proposed).

TESTED PRODUCT

No.	Items	Agreed	Moderately agreed	Not completely agreed	Not agreed	Positive answers
01	Your skin is more moisturized	60,0%	34,3%	2,9%	2,9%	94,3%
02	Your skin appears rested, revived, fresher	45,7%	48,6%	5,7%	0,0%	94,3%
03	Fine lines and wrinkles appear less evident	28,6%	42,9%	25,7%	2,9%	71,4%
04	Your skin appears smoother	40,0%	48,6%	8,6%	2,9%	88,6%
05	Your skin appears firmer and more tonic	37,1%	48,6%	14,3%	0,0%	85,7%
06	Your skin appears brighter	48,6%	42,9%	8,6%	0,0%	91,4%
No.	Items	Strongly	Improved	Unchanged	Aggravated	Positive answers
07	Skin dryness	22,9%	68,6%	8,6%	0,0%	91,4%
08	Visible signs of fatigue, tired look	11,4%	62,9%	25,7%	0,0%	74,3%
09	Lack of skin firmness and elasticity	20,0%	62,9%	17,1%	0,0%	82,9%
10	Wrinkles and expressions lines	11,4%	48,6%	40,0%	0,0%	60,0%
11	Lack of skin smoothness	17,1%	65,7%	17,1%	0,0%	82,9%

SUBSEQUENT USE OF THE PRODUCT

No.	Items	Luxe	Masstige	Mass market		Positive answers
12	According to you, this product is sold in which market segment?	20,0%	60,0%	20,0%	--	--
No.	Items	Very good	Good	Not good	Bad	Positive answers
13	What is your overall appreciation of this product in terms of efficacy?	34,3%	60,0%	2,9%	2,9%	94,3%
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
14	Would you continue using this product?	62,9%	28,6%	8,6%	0,0%	91,4%
No.	Items	All over the year	Only Spring and Summer			Positive answers
15	If you would you continue using this product, when would you apply it?	80,0%	20,0%	--	--	--
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
16	Would you buy this product independently from price?	31,4%	48,6%	20,0%	0,0%	80,0%
17	Would you suggest this product to your acquaintance?	60,0%	31,4%	8,6%	0,0%	91,4%

Legend

Positive answers → % of subjects who gave positive judgement as “agreed” or “moderately agreed”, “strongly” or “improved”, “very good” or “good”, “absolutely yes” or “maybe”. The percentages are rounded off, this is why the sum of these percentages may be different from 100%.



PLACEBO PRODUCT

No.	Items	Agreed	Moderately agreed	Not completely agreed	Not agreed	Positive answers
01	Your skin is more moisturized	42,9%	42,9%	11,4%	2,9%	85,7%
02	Your skin appears rested, revived, fresher	34,3%	45,7%	14,3%	5,7%	80,0%
03	Fine lines and wrinkles appear less evident	17,1%	48,6%	31,4%	2,9%	65,7%
04	Your skin appears smoother	28,6%	45,7%	22,9%	2,9%	74,3%
05	Your skin appears firmer and more tonic	34,3%	48,6%	17,1%	0,0%	82,9%
06	Your skin appears brighter	42,9%	40,0%	17,1%	0,0%	82,9%
No.	Items	Strongly	Improved	Unchanged	Aggravated	Positive answers
07	Skin dryness	17,1%	62,9%	20,0%	0,0%	80,0%
08	Visible signs of fatigue, tired look	5,7%	57,1%	37,1%	0,0%	62,9%
09	Lack of skin firmness and elasticity	8,6%	71,4%	17,1%	2,9%	80,0%
10	Wrinkles and expressions lines	11,4%	42,9%	45,7%	0,0%	54,3%
11	Lack of skin smoothness	17,1%	48,6%	31,4%	2,9%	65,7%
SUBSEQUENT USE OF THE PRODUCT						
No.	Items	Luxe	Masstige	Mass market		Positive answers
12	According to you, this product is sold in which market segment?	14,3%	62,9%	22,9%	--	--
No.	Items	Very good	Good	Not good	Bad	Positive answers
13	What is your overall appreciation of this product in terms of efficacy?	28,6%	54,3%	11,4%	5,7%	82,9%
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
14	Would you continue using this product?	57,1%	28,6%	11,4%	2,9%	85,7%
No.	Items	All over the year	Only Spring and Summer			Positive answers
15	If you would you continue using this product, when would you apply it?	77,1%	22,9%	--	--	--
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
16	Would you buy this product independently from price?	25,7%	48,6%	17,1%	8,6%	74,3%
17	Would you suggest this product to your acquaintance?	45,7%	40,0%	11,4%	2,9%	85,7%

Legend

Positive answers → % of subjects who gave positive judgement as “agreed” or “moderately agreed”, “strongly” or “improved”, “very good” or “good”, “absolutely yes” or “maybe”. The percentages are rounded off, this is why the sum of these percentages may be different from 100%.



CONCLUSIONS

On the basis of the obtained results, it is possible to conclude that the product

RIVOLI COSMÉTIQUES SA **Crème de Nuit Jeunesse N°02 lab-01759.18**

determined:

- an increase of skin moisturization by +28.5%* at T7 and by +40.5%* at T28;
- an increase of gloss parameter (related to improvement of skin radiance/brightness) by +29.3%* at T7 and by +43.9%* at T28;
- a decrease of R0 parameter (related to an increase of skin firmness) by -5.7%* at T7 and by -9.9%* at T28;
- an increase of R2 parameter (related to an improvement of skin elasticity) +6.5%* at T7 and by +11.8%* at T28;
- a decrease of Ra parameter (related to an improvement of skin smoothness) by -5.1%* at T28;
- at T28;
- a decrease of Rz parameter (related to an improvement of skin roughness) by -5.0%* at T28;
- a decrease of transepidermal water loss (related to an improvement of skin barrier condition/function) respectively by -4.0%* at T7 and by -4.4%* at T28.

* statistically significant vs baseline (T0).

* statistically significant vs baseline (T0) and vs placebo product.

Moreover, the pH mean value remains physiological 15 minutes after the first product use.

Finally, the tested product is positively judged by most of the subjects participating in the study for all the investigated aspects.

Principal experimenter

Dr Enza Cestone

Data analysis and report

Dr Federica Ruggeri

Quality control

Dr Francesca De Gennaro

